|
|
Vitamins In America
|
Third Party Literature
|
Gastrointestinal Disorders--Treatment with Iberogast® Bremer, W. Fischer, E. Nicolay, K. Summary The antispasmodic, anti-inflammatory and motility regulating effects of Iberogast® were studied in 15 patients with a variety of gastrointestinal disorders who received the recommended dose of 20 drops of Iberogast® 3 times a day. Clinical observations agreed well with the effects predicted by the drug's known pharmacological properties. A range of effects on the gastrointestinal tract provided effective relief of most symptoms. Iberogast® was extremely well tolerated and no adverse effects were reported in this study. Conclusion Although patients with peptic ulcer or erosive gastritis were receiving both systematic and local antacids, simultaneous administration of Iberogast® was required to relieve symptoms arising from associated disturbances of motility. The finding was particularly evident in patients with duodenal ulcer on ranitidine who continued to complain of a post-prandial feeling of heaviness. The symptom was most marked in those with poor muscular tone of the gastric fundus, and was effectively relieved by Iberogast®. Combination therapy with ranitidine and Iberogast® is advisable for upper gastrointestinal disorders. The striking success of Iberogast® in treating irritable colon--both spastic and atonic forms--completely removed the need for laxative or purgative preparations. Unlike metoclopramide and domperidone, no adverse effects of Iberogast® have been reported even after several months' therapy. ---------- Therapeutic Effect of Iberis Amara in Functional Gastric Disorders -- Iberogast® Rapidly Relieves Upper Abdominal Pain and Discomfort Brdckel, M.H. Summary In 30 to 50% of patients who present clinically with gastrointestinal symptoms, no organic cause can be found. The various descriptions of these complaints, such as autonomic dystonia, organic neurosis and psycho-somatic illness all suggest that psychological effects mediated by the autonomic nervous system can result in a wide range of organ dysfunction. However, it is important to realize that there is considerable overlap between purely functional failures of normal regulation and altered morphology. Gastritis, which was previously a common diagnosis, is now more often recognized as just one feature of several different conditions. A clinical study of 20 in-patients with gastrointestinal symptoms has shown that single therapy with Iberogast® is rapidly effective in achieving a lasting and marked reduction in the whole symptom complex which characterizes these gastrointestinal disorders. Conclusion It is clear from this study that these kinds of gastrointestinal disorders are typically associated with chronic symptoms that are often resistant to treatment. Additional treatment with drugs which act specifically on the stomach does not appear to be indicated. Iberogast® was extremely well tolerated and did not cause any reported adverse effects. ---------- Treatment of Drug Related Gastrointestinal Disorders -- Double Blind, Placebo Controlled Study of the Efficacy of Iberogast® Mac Lean, N. Summary The efficacy of Iberogast® compared to placebo was investigated in a two-week study of 40 patients suffering from drug-related gastrointestinal disorders. The results revealed unequivocally the high efficacy and rapid onset of action of Iberogast® despite continued treatment with the drugs assumed to cause the gastrointestinal disorders (non-steroidal anti-inflammatory agents, cardiovascular and antithrombotic drugs). As compared to placebo a statistically significant improvement of almost all symptoms was observed. Iberogast® can therefore be recommended both as a therapeutic and prophylactic measure in cases where the primary disorder requires long-term treatment with drugs known to cause gastrointestinal symptoms. Conclusion Available evidence indicates that Iberogast® is well tolerated and effective in eliminating or reducing the gastrointestinal side effects of other drugs. ---------- Anti-Emetic Effect of Iberogast® Illing, G. Summary The previously reported anti-emetic effects of Iberogast® were studied objectively in a clinical study of 18 in-patients aged between 32 and 84 years. Most had severe underlying disorders characterized by moderate to marked nausea. Patients received the recommended dose of 20 drops 3 times a day for up to 14 days. A clear effect was observed after two days' treatment. After 5 days' treatment there was no further vomiting or nausea, except in one patient who had some residual symptoms. The experience of previous studies--that IberogasP is extremely well tolerated--was confirmed. Conclusion The results of this study show convincingly that Iberogast® is both effective and well tolerated in the treatment of vomiting and nausea. We believe that the absence of any centrally mediated pharmacological effect indicated by other studies is a particular advantage in reducing the occurrence of adverse drug effects. ---------- Treatment of Drug Related Gastrointestinal Symptoms with Iberogast® - A Double Blind, Placebo Controlled Study in 20 Patients Mac Lean, N. Summary The efficacy of Iberogast® was examined in a placebo controlled study of 20 patients with drug-induced gastrointestinal side effects. Treatment with Iberogast® was associated with a rapid and statistically significant improvement in practically all symptoms as compared with placebo. During the study, patients continued to take the drugs believed to be the cause of their gastrointestinal symptoms (mainly non-steroidal anti-inflammatory or cardiovascular drugs). The effectiveness of treatment with Iberogast® may reflect the view that pathophysiological changes in gastrointestinal motility underlie many functional disorders. However, morphological changes, stenosis, ulceration and diffuse inflammation can also lead to pathological changes in motility. Iberogast® is a well-tolerated drug with a sound pharmacological basis for use in a wide range of clinical conditions. Conclusion This study demonstrates the rapid onset of action and effectiveness of Iberogast® which is well tolerated in the treatment of gastrointestinal disorders. Its rapid onset of action and low incidence of side effects make Iberogast® especially useful in the treatment of drug related symptoms associated with poorly tolerated medication. ---------- Treatment of Functional Gastrointestinal Disorders with Iberogast® Bleimann, H. Summary The efficacy and compliance of Iberogast® was studied over a period of seven days in 25 in-patients with functional or drug-related gastro-enteropathy or gastro-oesophagitis. After 3 to 4 days' treatment, there was a clear improvement in symptoms and by 7 days, patients were virtually symptom-free. The treatment was well tolerated. No adverse effect clearly associated with Iberogast® was reported. Conclusion Physical symptoms were markedly and rapidly reduced after just one or two days treatment with Iberogast® whereas the effect on appetite was less precipitous. These observations are entirely compatible with the pharmacological properties of this preparation which include both motility regulating and anti-spasmodic effects. The effect on appetite, which relates to the autonomic system and functional dysregulation, may reflect an improvement in delayed gastric emptying. Iberogast® was well-tolerated even in elderly patients with relatively severe conditions. The results of this study demonstrate that Iberogast® is a rapidly and consistently effective form of therapy with a low risk-benefit ratio, even in elderly patients and those with severe underlying disease. These favourable effects may well reflect the absence of centrally mediated pharmacological effects. ---------- Treatment of Non-Specific Upper Gastrointestinal Symptoms in Elderly Patients Hdlscher, H.J. Summary With advancing age the incidence of non-specific gastroenterologic symptoms increases rapidly. Multiple symptoms leading to multiple therapy restricts the choice of drug required to relieve all symptoms and be adequately tolerated. Harmless drugs based on phytotherapy have been successfully applied in gastroenterology and are becoming increasingly a focus for pharmacological research. In a clinical trial of 24 patients in a nursing home, Iberogast® was shown to be very effective and well tolerated, even in those with multiple symptoms on combinations of drug treatments. Conclusion Owing to the fact that Iberogast® was extremely well tolerated--there were no reports of any adverse effects--long term treatment with Iberogast® for maintainance of maximum therapeutic effect appears to be uncomplicated. Only infrequently, when single symptoms are resistant to treatment, would a more specifically targeted treatment seem appropriate. And in such cases treatment with Iberogast® should not be discontinued. This study demonstrates that the combination of wide spectrum activity plus the fact that Iberogast® is extremely well tolerated, even in the elderly, confers a clear advantage. ---------- Daily Oral Treatment: How Long Can the Stomach Tolerate It? Ohms, P. Summary A therapeutic preparation of Iberis amara and other medications based on plants were studied in 20 patients from a health clinic who were suffering from functional and drug related gastro-intestinal disorders. Most patients were also suffering from moderate or severe concomitant illnesses. Interim results after 6 days' treatment showed total disappearance of initial symptoms in the great majority of cases. The treatment was very well tolerated and no adverse effects were reported. Conclusion The effects of treatment in this study have been convincingly demonstrated. No adverse effects were reported, even in patients receiving higher than average doses of medication. Of particular importance is the finding that other medications became better tolerated during treatment with Iberogast® which indicates that Iberogast® is a particularly useful drug, both therapeutically and prophylactically, in patients on long term therapy with poorly tolerated medication. ---------- Double Blind Trial of Metoclopramide and Iberogast® in Functional Gastroenteropathy Nicolay, K. Summary The study was performed in 77 patients aged between 18 and 60 years. The therapeutic effect of the two preparations was similar for all symptoms. The results also indicate that Iberogast® can eliminate or markedly reduce all symptoms of functional gastroenteropathy without incurring the central neurological effects associated with metoclopramide. Compliance was also better with Iberogast® which clearly has relevance for elderly patients on long term treatment. Objective measurements of the effects of malabsorption and malnutrition were reduced, as were subjective symptoms such as anorexia upper abdominal discomfort, nausea and vomiting, dysphagia, flatulence and retrostemal pain. Conclusion The results of this study show that the effectiveness of Iberogast® is equal to that of metoclopramide in relieving non-specific gastrointestinal symptoms with virtual absence of adverse drug effects. However, the therapeutic efficacy of Iberogast® is achieved without any recognizable effect on the central nervous system. |
|
Vitamins In America |
|
|
